PPARG and obesity due to melanocortin 4 receptor deficiency: In addition, methods to increase circulating adiponectin levels including PPARγ agonists or methods leading to upregulation of adiponectin receptors and/or development of specific adiponectin receptor agonists (e.g. osmotin) (Kadowaki and Yamauchi, 2005), could prove beneficial in several obesity related malignancies.